Reprogrammed Glia Improve Symptoms in a Mouse Model of Parkinson’s

By converting glial cells into dopaminergic neurons, scientists were able to partially rescue motor behavior in mice.

Apr 10, 2017
Diana Kwon


Parkinson’s, a neurodegenerative disease that primarily affects the motor system, is marked by a progressive loss of dopaminergic neurons in the brain. While current treatments are aimed at replenishing dopamine levels, none are able to restore the lost cells. Now, scientists have devised a way to reprogram glial cells into active dopamine neurons that can partially restore motor function in a mouse model of Parkinson’s. This proof-of-principle study could pave the way to a new treatment for the disease, researchers reported today (April 10) in Nature Biotechnology.

“In Parkinson’s disease, dopamine neurons die, but at the same time, because of inflammation . . . some glial cells become reactive and proliferate,” said coauthor Ernest Arenas, a molecular neurobiologist at the Karolinska Institute in Sweden. “So we thought that one interesting possibly for reprogramming could be to turn these [glial] cells . . . into the cells that are missing in the disease.”

Arenas and colleagues first tested this technique in vitro, by infecting human astrocytes—star-shape glial cells that are abundant in the brain—with viruses containing three transcription factors involved in neuronal identity and growth, a dopaminergic neuron-specific microRNA, and several small molecules that promote chromatin remodeling and aid brain development.

The researchers were able to successfully transform up to 16 percent of human astrocytes into dopaminergic neurons that were capable of firing action potentials in vitro. “We were really amazed by the physiological properties of the cells,” Arenas told The Scientist. “The reprogrammed cells had fantastic electrophysiology that is difficult to get in stem cell–derived cells.”

When the team applied this protocol to a mouse model of Parkinson’s (in which dopaminergic neurons in the striatum are killed by a toxin), the rodents displayed improved motor behavior and gait control. “The major achievement of this study is that, for the very first time, they show a behavioral effect achieved by reprogrammed neurons,” Magdalena Götz, a neuroscientist at the Ludwig-Maximilians-University Munich in Germany who was not involved with this study, told The Scientist. While many groups have converted various glial cells into neurons both in vitro and in vivo, she added, none had reported a corresponding change in behavior, until now.

“Generating in vivo dopaminergic neurons is an excellent way to replace the current L-dopa approach [to treating Parkinson’s],” said Gong Chen, a life sciences professor at Pennsylvania State University who was not involved in the work. L-dopa, or Levodopa, is a dopamine precursor that is commonly prescribed to treat the symptoms of Parkinson’s disease. “By regenerating dopaminergic neurons locally, you can greatly reduce the desensitization of dopamine receptors all over the brain,” Chen added. However, he pointed out that the reprogramming efficiency in the current study was relatively low. In a recent study, Chen’s group was able to reprogram up to 90 percent of astrocytes in mouse cortices in vivo.

Arenas acknowledged that because his team’s method is still an early prototype, there is still significant room for progress. “Our first focus will be to improve the reprogramming efficiency,” he said. He also noted that the group currently requires transgenic mice to selectively express the injected genes in astrocytes. In order to make this technique feasible for human testing, the team plans to explore ways to allow the virus to specifically target glial cells without a genetically modified host.

Over the last decade, glial reprogramming has piqued the interest of many researchers who see it as a promising method to treat neurodegenerative disease and brain injury by replenishing lost neurons. “During the last 10 to 15 years, this field moved incredibly fast from a strange approach to a fairly accepted approach attracting many researchers,” said Götz, who was one of the first to successfully convert glia into neurons in vitro.

“I predict that this is going to be the next frontier in regenerative medicine—we don’t need to inject any external stem cells anymore, we can just use internal glial cells,” Chen said. “I think this field will continue to thrive.”

P. Rivetti di Val Cervo et al., “Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model,” Nature Biotechnol., doi:10.1038/nbt.3835, 2017.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets


Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!